Efficacy of clobetasol spray: Factors beyond patient compliance

Journal of Dermatological Treatment

Volumn 23, Issue 1, 2012, Pages 11-15

  Bhutani, Tina ^a   Koo, John ^a   Maibach, Howard I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clobetasol propionate; Clobetasol spray; Skin penetration; Vehicle metamorphosis

Indexed keywords

CLOBETASOL PROPIONATE;

AEROSOL; ARTICLE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FOAM; HUMAN; OINTMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SKIN PENETRATION;

ANTI-INFLAMMATORY AGENTS; CHEMISTRY, PHARMACEUTICAL; CLOBETASOL; HUMANS; MEDICATION ADHERENCE; PHARMACEUTICAL VEHICLES; PSORIASIS; SKIN ABSORPTION;

EID: 84856002442     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2010.512952     Document Type: Article

References (28)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996; 14(3):485-496. (Pubitemid 26249398)
2. US Food and Drug Administration, Center for Drug Evaluation and Research. Clobex (clobetasol propionate) 0.05% spray. NDA 21-835 clinical pharamcology and bio-pharmaceutics review. 2005 July cited 2010 April 28. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2005/021835s000-ClinPharmR. pdf.
3. Beutner K, Chakrabarty A, Lemke S, Yu K. An intra-indivi-dual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque-type psoriasis. J Drugs Dermatol. 2006;5: 357-360.
4. Jarratt MT, Clark SD, Savin RC, Swinyer LJ, Safley CF, Brodell RT, et al. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque type psoriasis. Cutis. 2006;78:348-354. (Pubitemid 44952097)
5. Jacobsen C, Cornell RC, Savin RC. A comparison of clobe-tasol propionate 0.05% ointment and an optimized beta-methasone dipropionate 0.05% ointment in the treatment of psoriasis. Cutis. 1986;37:213-214.
6. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7: 185-192. (Pubitemid 36859094)
7. Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol. 2002;41:269-274. (Pubitemid 34773449)
8. Mraz S, Leonardi CL, Colon LE, Johnson LA. Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasis. J Dermatolog Treat. 2008;19:354-359.
9. Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: A review of newer publications. J Clin Dermatol. 2009;10(6):397-406.
10. Tanojo H, Huang X, Maibach HI. Foam for enhanced topical delivery: An overview. Dermatol Sinica. 2007;25:10-15. (Pubitemid 46422885)
11. Wester RC, Maibach HI. Cutaneous pharmacokinetics: 10 steps to percutaneous absorption. Drug Metab Rev. 1983;14(2):169-205. (Pubitemid 13143275)
12. Surber C, Smith EW. The mystical effects of dermatological vehicles. Dermatology. 2005;210:157-168. (Pubitemid 40463206)
13. Davis AF, Hadgraft J. Effect of supersaturation on membrane transport: 1. Hydrocortisone acetate. Int J Pharm. 1991; 76(1-2):1-8.
14. Purdon CH, Haigh JM, Surber C. Foam drug delivery in dermatology: Beyond the scalp. Am J Drug Deliv. 2003;1: 71-75.
15. Bouwstra JA, Dubbelaar FE, Gooris GS, Ponec M. The lipid organisation in the skin barrier. Acta Derm Venereol Suppl. 2000;208:23-30.
16. Williams ML, Elias PM. The extracellular matrix of stratum corneum: Role of lipids in normal and pathologic function. Crit Rev Ther Drug Carrier Syst. 1987;3(2): 95-122. (Pubitemid 17219200)
17. Barry BW. Drug delivery routes in the skin: A novel approach. Adv Drug Deliv Rev. 2002;S4(suppl 1):S31-S40.
18. Michaels AS, Chandrasekaran SK, Shaw JE. Drug permeation through human skin: Theory and in vitro experimental measurement. AIChE J. 1975;21(5):985-996.
19. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56:603-618. (Pubitemid 38326936)
20. Trommer H, Neubert RHH. Overcoming the stratum corneum: The modulation of skin penetration. Skin Pharmacol Physiol. 2006;19:106-121. (Pubitemid 43725821)
21. Thong HY, Zhai H, Maibach HI. Percutaneous penetration enhancers: An overview. Skin Pharmacol Physiol. 2007;20: 272-282. (Pubitemid 350014982)
22. Chowhan ZT, Pritchard R. Effect of surfactants on the percutaneous absorption of naproxen I: Comparisons of rabbit, rat, and human excised skin. J Pharm Sci. 1978;67: 1272-1274. (Pubitemid 9014467)
23. Friend D, Catz P, Heller J, Reid J, Baker R. Simple alkyl esters as skin permeation enhancers. J Control Release. 1989; 9:33-41. (Pubitemid 19155970)
24. Mohimi HR, Barry BW, Williams AC. Stratum corneum and barrier performance: A model lamellar structural approach. In: Bronaugh RL, Maibach HI, editors. Percutaneous absorption. New York, NY: Marcel Dekker; 2009. p. 515-554
25. Smith EW, Maibach HI, editors. Percutaneous penetration enhancers. 2nd ed. Boca Raton, FL: CRC Press; 2005.
26. Cornell RC, Stoughton RB. Correlation of the vasoconstric-tion assay and clinical activity in psoriasis. Arch Dermatol. 1985;121(1):63-67. (Pubitemid 16225021)
27. Loncin M, Roth T, Bornhardt C. Influence of surface active agents on the drying rate of solids. In: Toei R, Mujumdar AS, editors. Drying 85'. New York: Hemisphere Publ Corp; 1985. p. 97-101. (Pubitemid 16563050)
28. Clobex spray package insert. Dallas, TX: Galderma; 2007.